Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thor Medical ASAOSL:TRMED +1.05%26 FCF Yield % is -7.74 as of Jul. 16, 2026. GuruFocus rates OSL:TRMED with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Thor Medical ASA ranks better than 54.08% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thor Medical ASA FCF Yield % Related Terms
Thor Medical ASA FCF Yield % Historical Data
* Premium members only.
The historical data trend for Thor Medical ASA's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:TRMED vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Thor Medical ASA's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thor Medical ASA FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thor Medical ASA's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Thor Medical ASA's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thor Medical ASA (OSL:TRMED) has a FCF Yield % of -7.74 as of Jul. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Thor Medical ASA and its competitors. According to the industry distribution chart, Thor Medical ASA ranks #647 out of 1409 companies in the Biotechnology industry, placing it in the top 45.9%.
Is Thor Medical ASA's FCF Yield % too high?
Thor Medical ASA's current FCF Yield % is -7.74. Based on the distribution chart, Thor Medical ASA ranks #647 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Thor Medical ASA has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #647 out of 1409 companies for FCF Yield %. This puts Thor Medical ASA in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Thor Medical ASA and its competitors. Thor Medical ASA's current FCF Yield % is -7.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (OSL:TRMED) has a current FCF Yield % of -7.74. The current FCF Yield % is -7.74. Thor Medical ASA's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Thor Medical ASA (OSL:TRMED), the current FCF Yield % is -7.74 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
26GF Score
Get the complete analysis for OSL:TRMED
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:TRMED has been successfully added to your 
